GO:0097294 'de novo' XMP biosynthetic process: Purine Nucleotide Biosynthesis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097294 describes the de novo formation of xanthosine monophosphate (XMP) from simpler precursors, a central step in guanine nucleotide biosynthesis.
• The pathway converts IMP to XMP via IMP dehydrogenase (IMPDH) and then XMP to GMP via GMP synthetase (GMPS), with the latter requiring ATP and glutamine.
• IMPDH is a validated drug target in cancer, antiviral, and immunosuppressive therapies, and its activity is modulated by viral proteins such as EBV LMP1.
• De novo GMP synthesis, including XMP formation, is essential for developmental processes such as axon guidance in Drosophila.
• The ykkC riboswitch family senses purine intermediates like XMP, linking metabolite levels to gene regulation.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of XMP biosynthetic enzymes in disease and development.
Description
The Gene Ontology term GO:0097294, 'de novo' XMP biosynthetic process, defines the chemical reactions and pathways that build xanthosine monophosphate (XMP) from simpler precursors. XMP is a branch-point intermediate in purine metabolism, formed by the oxidation of inosine monophosphate (IMP) and subsequently aminated to guanosine monophosphate (GMP). This pathway is essential for supplying guanine nucleotides required for RNA, DNA, and protein synthesis, as well as for GTP-dependent signaling. Researchers study this process to understand fundamental nucleotide homeostasis and to target enzymes like IMPDH and GMPS in cancer, infections, and immune disorders. The de novo XMP biosynthetic process is highly conserved from bacteria to humans, and its enzymes are subject to complex allosteric and transcriptional regulation. In humans, IMPDH exists as two isoforms (IMPDH1 and IMPDH2) that catalyze the NAD+-dependent conversion of IMP to XMP, while GMPS catalyzes the ATP-dependent amination of XMP to GMP using glutamine as a nitrogen donor. The pathway intersects with salvage pathways and is critical for maintaining guanine nucleotide pools. Dysregulation of XMP biosynthesis has been implicated in oncogenesis, viral pathogenesis, and developmental disorders. For example, the Epstein-Barr virus latent membrane protein 1 (LMP1) subverts IMPDH pathways to drive B-cell oncometabolism, and loss of de novo GMP synthesis impairs axon guidance in Drosophila. Understanding the molecular details of this pathway provides a foundation for therapeutic intervention and for interpreting genetic variants in purine metabolism.
'de novo' XMP biosynthetic process At A Glance
| GO ID | GO:0097294 |
|---|---|
| GO term | 'de novo' XMP biosynthetic process |
| Ontology | biological_process |
| Synonym | 'de novo' XMP anabolism; 'de novo' XMP biosynthesis; 'de novo' XMP formation; 'de novo' XMP synthesis |
| Major function | Synthesis of xanthosine monophosphate (XMP) from simpler precursors, a key step in guanine nucleotide biosynthesis |
| Key enzymes | IMPDH (inosine monophosphate dehydrogenase), GMPS (GMP synthetase) |
| Substrates | IMP (inosine monophosphate), NAD+, glutamine, ATP |
| Products | XMP, then GMP |
| Pathway context | Purine metabolism; de novo GMP biosynthesis |
What Is GO:0097294?
GO:0097294 'de novo' XMP biosynthetic process is the biological process in which xanthosine monophosphate (XMP) is synthesized from simpler precursors, such as IMP, through enzymatic steps. It is a subpathway of purine nucleotide biosynthesis and is synonymous with 'de novo' XMP anabolism, biosynthesis, formation, or synthesis.
Why Is 'de novo' XMP biosynthetic process Important in Cell Biology?
The de novo XMP biosynthetic process is essential for maintaining cellular guanine nucleotide pools, which are required for DNA and RNA synthesis, energy transfer, and signal transduction. Its dysregulation is linked to cancer, viral infections, and developmental defects, making its enzymes attractive drug targets.
• Provides precursors for GMP, GDP, and GTP, essential for nucleic acid and protein synthesis.
• IMPDH inhibitors are used clinically as immunosuppressants, antivirals, and anticancer agents.
• Viral pathogens such as Epstein-Barr virus hijack IMPDH to reprogram B-cell metabolism.
• De novo GMP synthesis is required for axon guidance during neural development.
• Riboswitches such as ykkC sense XMP and related purines to regulate gene expression.
• The pathway is conserved across species, enabling comparative studies in model organisms.
• Genetic variants in IMPDH1 cause retinal degeneration, highlighting its role in tissue-specific homeostasis.
• Targeting XMP biosynthesis offers strategies for antimicrobial and antiparasitic therapy.
What Happens During 'de novo' XMP biosynthetic process?
Conversion of IMP to XMP by IMPDH
In simple terms: The cell takes a basic purine building block and modifies it to create a new intermediate.
The first committed step of XMP biosynthesis is the NAD+-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), catalyzed by inosine monophosphate dehydrogenase (IMPDH). This reaction introduces an oxygen at the C2 position of the purine ring, forming the xanthine base. IMPDH is a tetrameric enzyme that undergoes conformational changes during catalysis, and its kinetic mechanism has been characterized in detail. In humans, two isoforms, IMPDH1 and IMPDH2, exist with distinct tissue distributions and regulatory properties.
Amination of XMP to GMP by GMPS
In simple terms: The intermediate is then converted into a fully formed guanine nucleotide.
XMP is subsequently converted to guanosine monophosphate (GMP) by GMP synthetase (GMPS), which uses ATP and glutamine as substrates. GMPS catalyzes a two-step reaction: adenylylation of XMP to form adenylosuccinate-like intermediate, followed by amination using glutamine as the nitrogen donor. This enzyme is a member of the glutamine amidotransferase family and exhibits allosteric regulation. The reaction consumes ATP and releases AMP and glutamate.
Allosteric and structural regulation of the pathway
In simple terms: The enzymes in this pathway can change shape to control how fast the process runs.
IMPDH and GMPS are regulated by allosteric mechanisms and post-translational modifications. For example, GMPS activity is modulated by its oligomeric state and by binding to other proteins. Structural studies have revealed that GMP synthetases form tetramers with distinct domains for glutamine hydrolysis and ATP pyrophosphatase activity. These regulatory features ensure that XMP and GMP production matches cellular demand for guanine nucleotides.
Integration with purine salvage and riboswitch control
In simple terms: The cell can also recycle purines, and RNA switches can sense when enough is made.
The de novo XMP biosynthetic process operates alongside purine salvage pathways that recycle bases from nucleic acid turnover. In some organisms, such as Tritrichomonas foetus, salvage enzymes are essential due to the absence of de novo synthesis. Additionally, riboswitches like the ykkC family bind XMP and related metabolites to regulate gene expression, providing feedback control. This integration ensures metabolic balance and energy efficiency.
Key Genes Involved in GO:0097294 'de novo' XMP biosynthetic process
The following genes and proteins are central to the de novo XMP biosynthetic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IMPDH1 | Catalyzes IMP to XMP oxidation | Retinal degeneration, cancer metabolism |
| IMPDH2 | Catalyzes IMP to XMP oxidation | Oncogenesis, antiviral targeting |
| GMPS | Catalyzes XMP to GMP amination | Allostery, structure-function studies |
| GMPS (Drosophila) | De novo GMP synthesis | Axon guidance |
| IMPDH (T. foetus) | IMP dehydrogenase | Parasite metabolism, drug targets |
| ykkC riboswitch | Senses XMP and purines | Gene regulation |
| LMP1 (viral) | Subverts IMPDH pathways | EBV oncometabolism |
| Purine salvage enzymes | Recycle purines | Comparative metabolism |
| ATP pyrophosphatase domain | Part of GMPS | Catalysis |
| Glutamine amidotransferase domain | Part of GMPS | Nitrogen transfer |
| NAD+ binding site | IMPDH cofactor | Redox regulation |
| IMP | Substrate for IMPDH | Metabolite sensing |
| XMP | Product of IMPDH, substrate for GMPS | Riboswitch ligand |
| GMP | End product of pathway | Nucleotide pool |
| GTP | Downstream product | Signaling |
| IMPDH1 mutant | Altered activity | Retinal disease models |
| GMPS mutant | Impaired amination | Developmental studies |
How Is 'de novo' XMP biosynthetic process Regulated?
The de novo XMP biosynthetic process is regulated at multiple levels. IMPDH is subject to allosteric inhibition by GMP and activation by ATP. GMPS is regulated by its oligomeric state and by interactions with other proteins. Transcriptional regulation of IMPDH and GMPS responds to cellular demand for guanine nucleotides. Additionally, riboswitches such as ykkC sense XMP to control gene expression in bacteria. Viral proteins like LMP1 can modulate IMPDH activity to support oncometabolism.
'de novo' XMP biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IMPDH1 | Retinitis pigmentosa | Knock-in mouse with patient mutation |
| IMPDH2 | Cancer proliferation | Knockout cancer cell lines |
| GMPS | Developmental defects | Drosophila knockout |
| LMP1 | EBV-driven lymphoma | B-cell overexpression |
| IMPDH (T. foetus) | Parasite metabolism | Enzyme inhibition assays |
Cancer and oncometabolism
IMPDH2 is overexpressed in many cancers and supports increased guanine nucleotide synthesis required for proliferation. Epstein-Barr virus LMP1 subverts IMPDH pathways to drive B-cell oncometabolism, highlighting a viral-cancer link. Inhibitors of IMPDH are being explored as anticancer agents.
Retinal degeneration
Mutations in IMPDH1 cause autosomal dominant retinitis pigmentosa and Leber congenital amaurosis, likely due to altered enzyme activity and nucleotide imbalance in photoreceptors.
Developmental and neurological disorders
De novo GMP synthesis is required for axon guidance in Drosophila, and disruption leads to neural wiring defects. This suggests that XMP biosynthetic enzymes may play roles in neurodevelopment.
Infectious diseases
Parasites like Tritrichomonas foetus rely on purine salvage, but IMPDH is still a potential drug target. Antiviral strategies often target host IMPDH to limit viral replication.
From 'de novo' XMP biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IMPDH1 mutation affect retinal function? | Knock-in mouse |
| Is IMPDH2 required for tumor growth? | Knockout cancer cell line |
| How does GMPS allostery regulate flux? | Point mutation in GMPS |
| Can LMP1 drive oncometabolism via IMPDH? | Overexpression in B cells |
| What is the role of XMP in axon guidance? | Drosophila knockout |
| Does ykkC riboswitch respond to XMP? | Reporter assay with point mutations |
How to Study the 'de novo' XMP biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | XMP, IMP, GMP levels | Pathway flux |
| Enzyme kinetics | Catalytic parameters | IMPDH/GMPS mechanism |
| X-ray crystallography | Protein structure | Allosteric sites |
| CRISPR knockout | Gene function | Cancer cell growth |
| Stable isotope tracing | Metabolic flux | Oncometabolism |
| Riboswitch reporter assay | RNA-ligand binding | Gene regulation |
| Western blot | Protein expression | IMPDH2 levels |
Metabolomics and flux analysis
Mass spectrometry-based metabolomics can quantify XMP, IMP, and GMP levels to assess pathway activity. Stable isotope tracing can measure flux through IMPDH and GMPS.
Enzyme kinetics and structural biology
Recombinant IMPDH and GMPS can be purified for kinetic assays and crystallography to study mechanisms and allostery. These methods reveal substrate binding and catalytic residues.
Genetic screens and CRISPR models
CRISPR knockout or point mutation models allow functional dissection of IMPDH and GMPS in cells and organisms. Overexpression models can test gain-of-function effects.
Riboswitch and RNA-based assays
In vitro transcription and ligand-binding assays can characterize riboswitch regulation by XMP. Reporter gene fusions enable high-throughput screening.
How CRISPR Can Be Used to Study GO:0097294 'de novo' XMP biosynthetic process
Knockout
CRISPR knockout of IMPDH1, IMPDH2, or GMPS can abolish de novo XMP biosynthesis, leading to guanine auxotrophy and growth defects. These models are used to study pathway essentiality in cancer and development.
Point Mutation
Point mutations in IMPDH1 (e.g., R224P) are linked to retinal degeneration and can be introduced via CRISPR to model disease. Catalytic residue mutations in GMPS can dissect allosteric regulation.
Knock-in
Knock-in of tagged IMPDH or GMPS allows live-cell imaging and proteomic analysis of the pathway. Disease-associated alleles can be knocked into model organisms.
Overexpression
Overexpression of IMPDH2 or viral LMP1 can drive oncometabolism and increase XMP flux. This is useful for studying metabolic reprogramming in cancer.
How EDITGENE Supports 'de novo' XMP biosynthetic process Research
Researchers studying 'de novo' XMP biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in disease or development. EDITGENE provides custom CRISPR cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for 'de novo' XMP biosynthetic process research.
Frequently Asked Questions About 'de novo' XMP biosynthetic process
What is 'de novo' XMP biosynthetic process?
It is the biological process that synthesizes xanthosine monophosphate (XMP) from simpler precursors, such as IMP, as defined by GO:0097294.
What genes are involved in 'de novo' XMP biosynthetic process?
Key genes include IMPDH1, IMPDH2, and GMPS, which encode the enzymes that convert IMP to XMP and then to GMP.
What is the role of IMPDH in XMP biosynthesis?
IMPDH catalyzes the NAD+-dependent oxidation of IMP to XMP, the first committed step in guanine nucleotide synthesis.
How is XMP converted to GMP?
GMP synthetase (GMPS) converts XMP to GMP using ATP and glutamine.
Why is 'de novo' XMP biosynthesis important in cancer?
Cancer cells often upregulate IMPDH2 to meet increased demand for guanine nucleotides, and viral proteins like LMP1 can further stimulate this pathway.
What diseases are linked to IMPDH mutations?
Mutations in IMPDH1 cause retinal degeneration, including retinitis pigmentosa.
How can CRISPR be used to study XMP biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of IMPDH and GMPS in cells and organisms.
What is the ykkC riboswitch?
The ykkC riboswitch is an RNA element that senses XMP and related purines to regulate gene expression.
Is de novo GMP synthesis required for development?
Yes, studies in Drosophila show that de novo GMP synthesis is required for axon guidance.
What methods are used to measure XMP biosynthesis?
Metabolomics, enzyme kinetics, and isotope tracing are commonly used to quantify pathway activity.
Conclusion
The de novo XMP biosynthetic process (GO:0097294) is a fundamental metabolic pathway that supplies guanine nucleotides for nucleic acid synthesis and signaling. Its enzymes, IMPDH and GMPS, are regulated by allostery and are implicated in cancer, retinal degeneration, and developmental disorders. Continued research using CRISPR models and advanced metabolomics will uncover new therapeutic opportunities.
References
- 1. Ballut L et al.. 2023. GMP Synthetase: Allostery, Structure, and Function.. Biomolecules 13(9) PMID: 37759779
- 2. Burton EM et al.. 2025. Epstein-Barr virus latent membrane protein 1 subverts IMPDH pathways to drive B-cell oncometabolism.. PLoS Pathog 21(5):e1013092 PMID: 40367275
- 3. Long H et al.. 2006. De novo GMP synthesis is required for axon guidance in Drosophila.. Genetics 172(3):1633-42 PMID: 16322525
- 4. Wang CC et al.. 1983. Purine salvage by Tritrichomonas foetus.. Mol Biochem Parasitol 8(4):325-37 PMID: 6633566
- 5. Ballut L et al.. 2022. Tertiary and Quaternary Structure Organization in GMP Synthetases: Implications for Catalysis.. Biomolecules 12(7) PMID: 35883427
- 6. Nakamura J et al.. 1995. Biochemical characterization of human GMP synthetase.. J Biol Chem 270(13):7347-53 PMID: 7706277
- 7. Barth KM et al.. 2025. Decoding the Complex Functional Landscape of the ykkC Riboswitches.. Biochemistry 64(9):1983-1995 PMID: 40254862
- 8. Digits JA et al.. 1999. Kinetic mechanism of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase.. Biochemistry 38(8):2295-306 PMID: 10029522
